Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female patient, \>/= 18 years of age
Metastatic breast cancer
1st-line treatment with Herceptin initiated in 2002
Included in pharmaco-epidemiologic HERMINE study
You may not be if
Patient died before scheduled follow-up visit (March 2005)
Clareo Health | An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
